Healthcare
Elanco Animal Health Incorporated (ELAN)
Data as of July 16, 2026
Environment story
Elanco demonstrates moderate environmental commitment with product innovation targeting sustainability (Bovaer methane reduction, Experior ammonia reduction) but lacks comprehensive disclosed emissions data. Scope 1, 2, and 3 emissions are undisclosed, resulting in a 15-point deduction. No explicit net-zero target year disclosed, resulting in a 15-point deduction. The company shows awareness of climate-adjacent issues through farm animal sustainability products but provides insufficient transparency on its own operational carbon footprint and supply-chain emissions. No major environmental controversies identified in available filings, but the absence of granular ESG reporting limits credibility assessment.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
Bovaer (3-NOP) Methane ReductionFDA-approved methane-reducing feed ingredient for lactating dairy cattle; reduces livestock environmental impact via reduced enteric emissionsDirect supply-chain emission reduction in farm animal customers' operations; launched Q3 2024
-
Experior Ammonia ReductionInjectable product that reduces ammonia gas emissions from cattle waste; expanded use approved in October 2024 for heifersEnvironmental benefit to farm animal producers; targets ~40% of U.S. fed cattle population
Social story
Elanco demonstrates foundational social commitment through employee development programs, ERG infrastructure, and explicit diversity council initiatives. However, quantitative social metrics remain largely undisclosed. CEO-to-median-worker pay ratio not disclosed; no active union-suppression activities documented. Workforce diversity percentages (women, URG representation in executive/board roles) are not disclosed in the 10-K filing. The company reports 9,400 full-time and 500 fixed-duration employees as of December 31, 2025, with approximately 30% U.S.-based workforce. No documented labor strikes or NLRB complaints within 24 months. Supply-chain ethics and human-rights audit practices are not explicitly detailed. Eight ERGs and employee-led councils signal institutional diversity commitment, but quantitative verification is absent.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
Eight Elanco Employee Resources Groups (ERGs)ERGs serve as employee-led communities offering support and professional development; any employee eligible to join any ERG; aligned with inclusive culture commitmentSupports retention and professional development; signals diversity infrastructure
-
Employee-Led & Leadership-Supported Human Capital CouncilInfluences strategic direction of human capital management; represents global sites and affiliatesGovernance structure for diversity and inclusion strategy
-
Pay-for-Performance PhilosophyAnnual benchmarking of total rewards against peers; merit increases and recognition programsSupports competitive talent attraction and retention
-
Learning, Mentoring & Development OpportunitiesCareer advancement pathways; skills development aligned with industry evolutionSupports employee skill development and retention
Governance story
Elanco operates with single-class share structure (no dual-class voting penalty applied). Board independence percentage not disclosed in 10-K excerpt, preventing assessment against 75% threshold. Lobbying expenditures and political-contribution totals are not disclosed. The company operates under FDA, USDA, EPA, and international regulatory frameworks with no disclosed active antitrust, financial-fraud, or consumer-safety proceedings. A 2025 Restructuring Plan was announced in December 2025 with $155 million in charges incurred and $25-30 million expected in 2026, signaling active governance of operational efficiency. No evidence of litigation against shareholder climate proposals. Governance disclosure is limited; quantitative independence and lobbying data absent.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
2025 Restructuring PlanBoard-approved December 2025; supports margin expansion, optimizes manufacturing and R&D footprints, invests in innovation; includes closure of Monheim animal study facility by end of 2026 and Kansas City manufacturing facility by end of 2026$155M pre-tax charges in 2025; $25-30M expected 2026; targets global headcount reduction of ~300 with 300 replacement positions in growth/lower-cost geographies
-
Global Compliance & Regulatory FrameworkCompliance processes across FDA, USDA, EPA, EMA, MAPA, MARA, VMD and other regulatory bodies; dedicated regulatory function manages approvals, post-approval monitoring, pharmacovigilanceEnsures legal and regulatory compliance across 90+ countries
These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Elanco Animal Health Incorporated. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Elanco Animal Health Incorporated in the app for interactive charts and portfolio building.
Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics